The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Phase III Trial for Patients With mCSCC Who Progress After First-line Chemotherapy

Danny Rischin, MD, MBBS, FRACP
Published Online:4:59 PM, Mon November 19, 2018


Danny Rischin, MD, MBBS, FRACP, director, division of cancer medicine, and head, department of medical oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses an ongoing phase III trial for patients with metastatic cutaneous squamous cell carcinoma or recurrent disease after progressing on frontline chemotherapy. 

These patients are usually treated with a platinum-Taxol and bevacizumab (Avastin), but there are very few options after that, Rischin says. Survival rates after progression have also been very poor. 

According to Rischin, this phase III trial is randomizing patients to sunitinib (Sutent) or a second-line chemotherapy agent.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.